{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:41:19Z","timestamp":1767894079496,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.euf.2016.08.012","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T11:50:28Z","timestamp":1473767428000},"page":"355-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Human Papillomavirus Infection and Vaccination in Males"],"prefix":"10.1016","volume":"2","author":[{"given":"Eugenio","family":"Ventimiglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Horenblas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2016.08.012_bib0235","unstructured":"International Agency for Research on Cancer. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 90; 2007."},{"key":"10.1016\/j.euf.2016.08.012_bib0240","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"issue":"4 Suppl","key":"10.1016\/j.euf.2016.08.012_bib0245","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00007435-199904001-00002","article-title":"American Social Health Association Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States","volume":"26","author":"Cates","year":"1999","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.euf.2016.08.012_bib0250","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/ijc.29082","article-title":"EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection","volume":"136","author":"Giuliano","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2016.08.012_bib0255","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"De Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2016.08.012_bib0260","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/507432","article-title":"Prevalence of HPV infection among men: a systematic review of the literature","volume":"194","author":"Dunne","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.euf.2016.08.012_bib0265","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","article-title":"Updating the natural history of human papillomavirus and anogenital cancers","volume":"30","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0270","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of ten years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.euf.2016.08.012_bib0275","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines \u2014 immune responses","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0280","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.08.012_bib0285","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.08.012_bib0290","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/591095","article-title":"Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men","volume":"198","author":"Giuliano","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.euf.2016.08.012_bib0295","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/1055-9965.EPI-04-0754","article-title":"Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers","volume":"14","author":"Kjaer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euf.2016.08.012_bib0300","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/095646240001100203","article-title":"Asymptomatic penile HPV infection: a prospective study","volume":"11","author":"Wikstrom","year":"2000","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.euf.2016.08.012_bib0305","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(10)62342-2","article-title":"Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study","volume":"377","author":"Giuliano","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2016.08.012_bib0310","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/521192","article-title":"Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students","volume":"196","author":"Partridge","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.euf.2016.08.012_bib0315","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.eururo.2015.05.032","article-title":"Genital human papillomavirus infection progression to external genital lesions: the HIM study","volume":"69","author":"Sudenga","year":"2016","journal-title":"Eur Urol"},{"issue":"Suppl 6","key":"10.1016\/j.euf.2016.08.012_bib0320","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1016\/j.vaccine.2013.10.003","article-title":"Comprehensive control of human papillomavirus infections and related diseases","volume":"31","author":"Bosch","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0325","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2016.08.012_bib0330","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1016\/j.vaccine.2013.06.060","article-title":"Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review","volume":"31","author":"Fesenfeld","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2004.03.007","article-title":"EAU guidelines on penile cancer","volume":"46","author":"Solsona","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2016.08.012_bib0340","unstructured":"Pompeo ACL, Heyns CF. Penile cancer. Soci\u00e9t\u00e9 Internationale d\u2019Urologie; 2009."},{"key":"10.1016\/j.euf.2016.08.012_bib0345","unstructured":"American Cancer Society. Who should be vaccinated against HPV and when? www.cancer.org\/cancer\/cancercauses\/othercarcinogens\/infectiousagents\/hpv\/humanpapillomavirusandhpvvaccinesfaq\/hpv-faq-who-should-get-hpv-vaccines."},{"key":"10.1016\/j.euf.2016.08.012_bib0350","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2016.08.012_bib0355","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00345-008-0302-z","article-title":"Penile cancer: epidemiology, pathogenesis and prevention","volume":"27","author":"Bleeker","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2016.08.012_bib0360","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jcp.2008.063149","article-title":"Human papillomavirus prevalence and type distribution in penile carcinoma","volume":"62","author":"Miralles-Guri","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.euf.2016.08.012_bib0365","first-page":"1","article-title":"Biological agents. A review of human carcinogens","volume":"100B","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"10.1016\/j.euf.2016.08.012_bib0370","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/path.4405","article-title":"Pathogenic role of the eight probably\/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer","volume":"234","author":"Halec","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.euf.2016.08.012_bib0375","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","article-title":"Role of human papillomavirus in penile carcinomas worldwide","volume":"69","author":"Alemany","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2016.08.012_bib0380","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.juro.2014.08.087","article-title":"Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome","volume":"193","author":"Djajadiningrat","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2016.08.012_bib0385","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00345-014-1379-1","article-title":"Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs","author":"Capogrosso","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2016.08.012_bib0390","first-page":"465","article-title":"Human papillomavirus vaccines. WHO position paper, October 2014","volume":"89","author":"World Health Organization","year":"2014","journal-title":"World Health Organ Wkly Epidemiol Rec"},{"key":"10.1016\/j.euf.2016.08.012_bib0395","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction \u2014 the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0400","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2016.08.012_bib0405","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0410","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.vaccine.2016.02.040","article-title":"Adverse events following HPV vaccination, Alberta 2006-2014","volume":"34","author":"Liu","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.euf.2016.08.012_bib0415","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.vaccine.2006.05.119","article-title":"Chapter 11: HPV vaccines: commercial research & development","volume":"24","author":"Inglis","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0420","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euf.2016.08.012_bib0425","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2010.08.003","article-title":"In vivo mechanisms of vaccine-induced protection against HPV infection","volume":"8","author":"Day","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.euf.2016.08.012_bib0430","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.euf.2016.08.012_bib0435","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.euf.2016.08.012_bib0440","unstructured":"Food and Drug Administration. Clinical review of biologics license application supplement STN# 125126\/1297.0 \u2013 male indication for GARDASIL. 2009. www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM190977.pdf."},{"key":"10.1016\/j.euf.2016.08.012_bib0445","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S1470-2045(15)70075-6","article-title":"Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging","volume":"16","author":"Lowy","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2016.08.012_bib0450","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1016\/j.vaccine.2015.08.072","article-title":"Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years) \u2014 the MAM study","volume":"33","author":"Giuliano","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2016.08.012_bib0455","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"Br Med J"},{"key":"10.1016\/j.euf.2016.08.012_bib0460","first-page":"1","article-title":"Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study","volume":"3099","author":"Chow","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456916301353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456916301353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:45:28Z","timestamp":1762497928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456916301353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S2405456916301353"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2016.08.012","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human Papillomavirus Infection and Vaccination in Males","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2016.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}